AU2005315914B2 - Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease - Google Patents

Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease Download PDF

Info

Publication number
AU2005315914B2
AU2005315914B2 AU2005315914A AU2005315914A AU2005315914B2 AU 2005315914 B2 AU2005315914 B2 AU 2005315914B2 AU 2005315914 A AU2005315914 A AU 2005315914A AU 2005315914 A AU2005315914 A AU 2005315914A AU 2005315914 B2 AU2005315914 B2 AU 2005315914B2
Authority
AU
Australia
Prior art keywords
lower alkyl
compound
formula
halogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005315914A
Other languages
English (en)
Other versions
AU2005315914A1 (en
Inventor
Synese Jolidon
Robert Narquizian
Roger David Norcross
Emmanuel Pinard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2005315914A1 publication Critical patent/AU2005315914A1/en
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG Request for Assignment Assignors: F.HOFFMANN-LA ROCHE AG
Application granted granted Critical
Publication of AU2005315914B2 publication Critical patent/AU2005315914B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2005315914A 2004-12-15 2005-12-05 Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease Ceased AU2005315914B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106597 2004-12-15
EP04106597.0 2004-12-15
PCT/EP2005/012994 WO2006063709A1 (en) 2004-12-15 2005-12-05 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease

Publications (2)

Publication Number Publication Date
AU2005315914A1 AU2005315914A1 (en) 2006-06-22
AU2005315914B2 true AU2005315914B2 (en) 2011-03-03

Family

ID=35841863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005315914A Ceased AU2005315914B2 (en) 2004-12-15 2005-12-05 Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease

Country Status (20)

Country Link
US (1) US7375226B2 (enExample)
EP (1) EP1828200B1 (enExample)
JP (1) JP4709849B2 (enExample)
KR (1) KR100883003B1 (enExample)
CN (1) CN100586951C (enExample)
AR (1) AR052156A1 (enExample)
AT (1) ATE457989T1 (enExample)
AU (1) AU2005315914B2 (enExample)
BR (1) BRPI0519054A2 (enExample)
CA (1) CA2590316A1 (enExample)
DE (1) DE602005019465D1 (enExample)
ES (1) ES2338139T3 (enExample)
IL (1) IL183592A0 (enExample)
MX (1) MX2007006896A (enExample)
NO (1) NO20072833L (enExample)
NZ (1) NZ555476A (enExample)
RU (1) RU2007121768A (enExample)
TW (1) TWI299041B (enExample)
WO (1) WO2006063709A1 (enExample)
ZA (1) ZA200705044B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8889767B2 (en) 2009-02-06 2014-11-18 Styrolution GmbH Thermoplastic molding compounds based on styrene copolymers and polyamides having improved weathering resistance
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9090632B2 (en) * 2010-08-31 2015-07-28 Vanderbilt University Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9403835B2 (en) * 2011-12-22 2016-08-02 Ares Trading S.A. Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
RS67906B1 (sr) 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423847A1 (de) 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
JPH08325234A (ja) * 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
EE200000482A (et) * 1998-03-06 2002-02-15 Janssen Pharmaceutica N.V. Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
KR20010032967A (ko) * 1998-03-06 2001-04-25 디르크 반테 글리신 수송 저해제
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP2006512404A (ja) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
NZ544820A (en) 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
CN100522171C (zh) 2003-09-09 2009-08-05 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂、用于治疗精神病的1-苯甲酰基哌嗪衍生物
EP1663232B1 (en) 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses

Also Published As

Publication number Publication date
KR100883003B1 (ko) 2009-02-12
IL183592A0 (en) 2007-09-20
MX2007006896A (es) 2007-06-26
NZ555476A (en) 2009-09-25
JP4709849B2 (ja) 2011-06-29
NO20072833L (no) 2007-07-17
ZA200705044B (en) 2008-09-25
RU2007121768A (ru) 2009-01-27
EP1828200B1 (en) 2010-02-17
US20060128713A1 (en) 2006-06-15
TW200634017A (en) 2006-10-01
ATE457989T1 (de) 2010-03-15
KR20070086196A (ko) 2007-08-27
US7375226B2 (en) 2008-05-20
BRPI0519054A2 (pt) 2008-12-23
JP2008523126A (ja) 2008-07-03
DE602005019465D1 (de) 2010-04-01
CA2590316A1 (en) 2006-06-22
AU2005315914A1 (en) 2006-06-22
WO2006063709A1 (en) 2006-06-22
ES2338139T3 (es) 2010-05-04
CN101076532A (zh) 2007-11-21
TWI299041B (en) 2008-07-21
AR052156A1 (es) 2007-03-07
CN100586951C (zh) 2010-02-03
EP1828200A1 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
EP1828200B1 (en) Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease.
RU2736217C2 (ru) Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr)
CA2596636C (en) Heterocyclyl substituted phenyl methanones as inhibitors of the glycine transporter 1
CA2557541C (en) Pyrimidine derivatives
JP4890446B2 (ja) ドーパミンｄ３受容体に対してアフィニティーを有する化合物およびその使用
CA2797019C (en) Modulators of 5-ht receptors and methods of use thereof
AU2013394970B2 (en) Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation method and use thereof
CA2589192C (en) Phenyl-piperazin methanone derivatives
US7442710B2 (en) Substituted phenyl methanones
EP3097110A1 (en) New dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them
CN102947301A (zh) 喹嗪烷和吲嗪烷衍生物
JP4436460B2 (ja) チアゾロベンゾ複素環、それらの製造及びそれらを含有する医薬
AU605822B2 (en) Tricyclic benzimidazoles, processes for the preparation thereof and pharmaceutical compositions containing them
AU2005324109A1 (en) Benzoyl-tetrahydropyridine as GlyT-1 inhibitors

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: F. HOFFMANN-LA ROCHE AG

Free format text: FORMER NAME: F.HOFFMANN-LA ROCHE AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired